Ropinirole dosage

Population pharmacokinetic analysis of clinical study data showed that estrogens (mainly ethinylestradiol ) used in HRT reduced ropinirole clearance by one-third.In another analysis it was found that women taking HRT received a slightly lower daily dose of ropinirole than those not on HRT, with no difference in adverse effects. Therefore, in women already receiving HRT, ropinirole treatment may be started using the usual dose titration.However, it is suggested that a reduction in the ropinirole dosage may be needed if HRT is started, and an increase if it is withdrawn. 

Parkinson s disease. In one case the dosage of pergolide was halved and in two others ropinirole or entacapone were used as alternatives, in all cases with reduction of the hypersexual symptoms. The other four patients continued to take pergolide, with persistence of the symptoms, to which they and their partners adjusted. 

A 49-year-old man with Parkinson s disease was treated with ropinirole, and the dosage eventually reaching 3 mg tds. He had penile erections 20-30 minutes after each dose, lasting for 10-15 minutes. They were not associated with arousal and were very uncomfortable he had no history of sexual dysfunction. Their frequency diminished with a reduction in drug dosage, but they stopped completely only on drug withdrawal. 

Pramipexole is initiated at a dose of 0.125 mg three times a day and increased every 5 to 7 days as tolerated. In a fixed-dose study, daily doses of 3, 4.5, and 6 mg were not more effective than 1.5 mg/day, and the higher doses were associated with a higher frequency of adverse effects. When switching from bromocriptine or pergolide to pramipexole, a 10 1 and 1 1 dosage substitution is recommended, respectively. Ropinirole is initiated at 0.25 mg three times a day and increased by 0.25 mg three times a day on a weekly basis to a maximum of 24 mg/day. The dose of dopaminergic agonists is best determined by slow titration to enhance tolerance and to find the least dose that provides optimal benefit. 

In 33 patients with Parkinson s disease (mean age 63 years) who were taking a stable dosage of ropinirole in an immediate-release formulation, sleep disturbances improved or disappeared after they switched to a prolonged-release formulation, with improved subjective quality of sleep, reduced daytime sleepiness, and disappearance of sleep attacks [72 ]. The EIDOS and DoTS descriptions of sleep attacks due to dopamine receptor agonists are shown in Figure 4. 

---